Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

D Thompson1, D Easton,

  • 1CRC Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, United Kingdom. douglas@srl.cam.ac.uk

American Journal of Human Genetics
|February 15, 2001
PubMed
Summary

Germline BRCA2 mutations in the ovarian cancer cluster region (OCCR) significantly increase ovarian cancer risk and decrease breast cancer risk in female carriers. This genotype-phenotype correlation refines understanding of BRCA2 mutation impact on hereditary cancer syndromes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can We Miniaturize CT Technology for a Successful Mobile Stroke Unit Roll-Out?

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2023
Same author

Applying Mendelian randomization to appraise causality in relationships between smoking, depression and inflammation.

Scientific reports·2022
Same author

SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?

Nature genetics·2014
Same author

Breast cancer screening: time to target women at risk.

British journal of cancer·2013
Same author

Germline BRCA1 mutations increase prostate cancer risk.

British journal of cancer·2012
Same author

Genetic variants associated with predisposition to prostate cancer and potential clinical implications.

Journal of internal medicine·2012

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Germline BRCA2 mutations are linked to hereditary breast and ovarian cancer.
  • Understanding genotype-phenotype correlations is crucial for risk assessment and management.

Purpose of the Study:

  • To evaluate genotype-phenotype correlations in BRCA2 mutation carriers.
  • To define the ovarian cancer cluster region (OCCR) and assess its impact on cancer risk.

Main Methods:

  • Studied cancer occurrence in 164 families with breast/ovarian cancer and germline BRCA2 mutations.
  • Defined the OCCR using deviance statistics (nucleotides 3059-4075 and 6503-6629).
  • Estimated relative and absolute risks using conditional likelihood analysis.

Main Results:

Related Experiment Videos

  • Mutations within the OCCR were associated with a higher ovarian:breast cancer ratio in female carriers.
  • OCCR mutations significantly decreased breast cancer risk (RR=0.63) and increased ovarian cancer risk (RR=1.88).
  • Some evidence suggested lower prostate cancer risk for OCCR mutation carriers; no difference in male breast cancer risk was observed.

Conclusions:

  • The OCCR is a critical region in BRCA2 influencing cancer risk.
  • Mutation location within BRCA2 significantly impacts the risk of developing specific cancers.
  • Findings support the role of the RAD51-binding domain in mediating these genotype-phenotype correlations.